Ofer Gonen is CEO of MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Prior to his CEO appointment in 2022, Mr. Gonen served as CEO of Clal Biotechnology Industries Ltd. (TASE: CBI), Israel’s leading life science investment company, as well as a managing partner at the Anatomy Medical Technologies Fund. Mr. Gonen previously served as the General Manager of Biomedical Investments Ltd., a managing partner at Arte Venture Group, and held a variety of executive positions in the industry. Mr. Gonen received a B.Sc. in Physics, Mathematics and Chemistry from the Hebrew University of Jerusalem, and an M.A. in Economics and Finance from Tel Aviv University, with distinction. He graduated the prestigious “Talpiot” program of the Israeli Defense Forces.
In the face of these multifaceted threats, the need for innovative healthcare solutions becomes increasingly urgent. It underscores the vital role of the biopharmaceutical industry in not only addressing immediate health crises but also contributing to the broader resilience and well-being of humanity in times of adversity.